Literature DB >> 23185715

Stroke prevention with oral anticoagulation in older people with atrial fibrillation - a pragmatic approach.

Ali Ali1, Claire Bailey, Ahmed H Abdelhafiz.   

Abstract

With advancing age, the prevalence of both stroke and non valvular atrial fibrillation (NVAF) is increasing. NVAF in old age has a high embolic potential if not anticoagulated. Oral anticoagulation therapy is cost effective in older people with NVAF due to their high base line stroke risk. The current stroke and bleeding risk scoring schemes have been based on complex scoring systems that are difficult to apply in clinical practice. Both scoring schemes include similar risk factors for ischemic and bleeding events which may lead to confusion in clinical decision making to balance the risks of bleeding against the risks of stroke, thereby limiting the applicability of such schemes. The difficulty in application of such schemes combined with physicians' fear of inducing bleeding complications has resulted in under use of anticoagulation therapy in older people. As older people (≥75 years) with NVAF are all at high risk of stroke, we are suggesting a pragmatic approach based on a yes/no decision rather than a risk scoring stratification which involves an opt out rather an opt in approach unless there is a contraindication for oral anticoagulation. Antiplatelet agents should not be an alternative option for antithrombotic treatment in older people with NVAF due to lack of efficacy and the potential of being used as an excuse of not prescribing anticoagulation. Bleeding risk should be assessed on individual basis and the decision to anticoagulate should include patients' views.

Entities:  

Keywords:  anticoagulation; atrial fibrillation; older people

Year:  2012        PMID: 23185715      PMCID: PMC3501369     

Source DB:  PubMed          Journal:  Aging Dis        ISSN: 2152-5250            Impact factor:   6.745


  62 in total

1.  Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.

Authors:  David A Fitzmaurice; F D Richard Hobbs; Sue Jowett; Jonathon Mant; Ellen T Murray; Roger Holder; J P Raftery; S Bryan; Michael Davies; Gregory Y H Lip; T F Allan
Journal:  BMJ       Date:  2007-08-02

2.  Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation.

Authors:  Daniela Poli; Emilia Antonucci; Sophie Testa; Alberto Tosetto; Walter Ageno; Gualtiero Palareti
Journal:  Circulation       Date:  2011-08-01       Impact factor: 29.690

3.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

Authors:  Brian F Gage; Yan Yan; Paul E Milligan; Amy D Waterman; Robert Culverhouse; Michael W Rich; Martha J Radford
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

4.  Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall.

Authors:  Brian F Gage; Elena Birman-Deych; Roger Kerzner; Martha J Radford; David S Nilasena; Michael W Rich
Journal:  Am J Med       Date:  2005-06       Impact factor: 4.965

5.  Impact of new criteria for anticoagulant treatment in atrial fibrillation.

Authors:  Moisés Rodríguez-Mañero; Alberto Cordero; Vicente Bertomeu-González; José Moreno-Arribas; Vicente Bertomeu-Martínez; Pilar Mazón; Lorenzo Fácila; Juan Cosín; Iñaki Lekuona; Enrique Galve; José R González-Juanatey
Journal:  Rev Esp Cardiol       Date:  2011-06-08       Impact factor: 4.753

6.  Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline.

Authors:  Larry B Goldstein; Robert Adams; Mark J Alberts; Lawrence J Appel; Lawrence M Brass; Cheryl D Bushnell; Antonio Culebras; Thomas J Degraba; Philip B Gorelick; John R Guyton; Robert G Hart; George Howard; Margaret Kelly-Hayes; J V Ian Nixon; Ralph L Sacco
Journal:  Stroke       Date:  2006-05-04       Impact factor: 7.914

7.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

Review 8.  Status of the epidemiology of atrial fibrillation.

Authors:  William B Kannel; Emelia J Benjamin
Journal:  Med Clin North Am       Date:  2008-01       Impact factor: 5.456

9.  Short- and long-term prognosis for very old stroke patients. The Copenhagen Stroke Study.

Authors:  Lars Peter Kammersgaard; H S Jørgensen; J Reith; H Nakayama; P M Pedersen; T S Olsen
Journal:  Age Ageing       Date:  2004-03       Impact factor: 10.668

10.  Cost effectiveness of warfarin versus aspirin in patients older than 75 years with atrial fibrillation.

Authors:  Sue Jowett; Stirling Bryan; Jonathan Mant; Kate Fletcher; Andrea Roalfe; David Fitzmaurice; Gregory Y H Lip; F D Richard Hobbs
Journal:  Stroke       Date:  2011-04-21       Impact factor: 7.914

View more
  7 in total

1.  Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS2 Score ≥ 2: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?

Authors:  Séverine Henrard; Caroline Vandenabeele; Sophie Marien; Benoit Boland; Olivia Dalleur
Journal:  Drugs Aging       Date:  2017-11       Impact factor: 3.923

2.  The economic burden of ischemic stroke and major hemorrhage in medicare beneficiaries with nonvalvular atrial fibrillation: a retrospective claims analysis.

Authors:  Kathryn Fitch; Jonah Broulette; Winghan Jacqueline Kwong
Journal:  Am Health Drug Benefits       Date:  2014-06

Review 3.  Anemia: An Independent Predictor Of Adverse Outcomes In Older Patients With Atrial Fibrillation.

Authors:  Ali N Ali; Nandkishor V Athavale; Ahmed H Abdelhafiz
Journal:  J Atr Fibrillation       Date:  2016-04-30

4.  Stroke Prophylaxis for Atrial Fibrillation? To Prescribe or Not to Prescribe-A Qualitative Study on the Decisionmaking Process of Emergency Department Providers.

Authors:  Bory Kea; Tahroma Alligood; Cassandra Robinson; Josephine Livingston; Benjamin C Sun
Journal:  Ann Emerg Med       Date:  2019-05-09       Impact factor: 5.721

5.  Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study.

Authors:  Christopher Hohmann; Magnus Lutz; Sheila Vignali; Kathrin Borchert; Karolin Seidel; Sebastian Braun; Stephan Baldus; Michael Näbauer
Journal:  Thromb J       Date:  2022-07-04

6.  Warfarin slows deterioration of renal function in elderly patients with chronic kidney disease and atrial fibrillation.

Authors:  Chia-Chu Chang; Hung-Hsiang Liou; Chia-Lin Wu; Chirn-Bin Chang; Yu-Jun Chang; Ping-Fang Chiu; Ching-Hui Huang
Journal:  Clin Interv Aging       Date:  2013-05-10       Impact factor: 4.458

7.  Anticoagulation Stability Depends on CHADS2 Score and Hepatorenal Function in Warfarin-treated Patients, Including Those with Atrial Fibrillation.

Authors:  Keita Odashiro; Taku Yokoyama; Mitsuhiro Fukata; Takeshi Arita; Toru Maruyama; Koichi Akashi
Journal:  J Atheroscler Thromb       Date:  2016-06-16       Impact factor: 4.928

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.